Skip to main content

Table 1 Characteristics of the patients at baseline or during follow-up

From: Prognostic significance of visit-to-visit variability, and maximum and minimum LDL cholesterol in diabetes mellitus

 

All patients (n=5340)

Therapy Statusa

LDL variabilityb

Fenofibrate (n=2673)

Placebo (n=2667)

VIM <13.2

(n=2665)

VIM ≥13.2

(n=2675)

P

At baseline

Age

62.8±6.6

62.8±6.5

62.8±6.7

62.9±6.6

62.6±6.5

0.06

Female sex (n, %)

1632 (30.6)

817 (30.6)

815 (30.6)

770 (28.9)

862 (32.2)

0.008

Weight

94.9±18.3

94.6±18.2

95.2±18.5

95.6±17.9

94.3±18.7

0.009

Body-mass index

32.3±5.3

32.2±5.3

32.4±5.3

32.4±5.3

32.2±5.4

0.28

Waist circumference (cm)

107.7±13.5

107.5±13.3

107.8±13.7

108.1±13.4

107.2±13.6

0.02

Systolic blood pressure (mmHg)

133.9±17.7

133.8±17.6

133.9±17.9

132.2±17.2

135.5±18.1

<0.0001

Diastolic blood pressure (mmHg)

74.0±10.8

73.8±10.6

74.1±10.9

73.1±10.6

74.8±10.9

<0.0001

Fasting serum glucose (mg/dL)

175.8±54.6

176.3±54.1

175.3±55.1

170.7±51.8

180.8±56.8

<0.0001

Total cholesterol (mg/dL)

175.3±37.4

174.9±36.8

175.7±38.0

162.8±28.2

187.8±41.1

<0.0001

LDL cholesterol (mg/dL)

100.6±30.7

100.0±30.2

101.2±31.0

91.5±24

109.6±33.8

<0.0001

HDL cholesterol (mg/dL)

38.1±7.8

38.0±7.8

38.2±7.7

38.5±7.7

37.7±7.8

0.0005

Plasma triglyceride (mg/dL)

188.0±113

189.7±111,5

186.3±114.6

167±91.1

208.9±127.9

<0.0001

Serum creatinine (mg/dL)

0.92±0.22

0.93±0.23

0.93±0.22

0.92±0.23

0.93±0.21

0.04

Lipids during follow-up

Mean total cholesterol (mg/dL)

160.6±26.8

158.3±26.2

162.9±27.2*

156.9±23.6

164.3±29.1

<0.0001

Mean plasma triglyceride (mg/dL)

165.5±88.5

152.5±80.6

178.6±94.0*

151.4±72.6

179.5±100

<0.0001

Mean HDL cholesterol (mg/dL)

39.9±8.2

40.2±8.7

39.5±7.8*

40.5±8.3

39.2±8.1

<0.0001

Mean LDL cholesterol (mg/dL)

88.4±19.8

88.2±19.9

88.6±19.7

86.6±18.4

90.1±21.0

<0.0001

Maximum LDL cholesterol (mg/dL)

120.1±29.6

119.0±29.6

121.3±29.5*

107.4±22.7

132.8±30.2

<0.0001

Minimum LDL cholesterol (mg/dL)

64.2±17.8

64.7±17.5

63.7±18.0‡

68.2±17.1

60.1±17.5

<0.0001

LDL SD

19.3±8.8

18.7±8.8

19.9±8.8*

13.5±4.8

25.1±8.1

<0.0001

LDL CV (%)

22.1±9.2

21.4±9.0

22.7±9.4*

15.8±5.3

28.3±8.0

<0.0001

LDL VIM

13.9±6.0

13.8±6.0

14.1±5.9

9.3±2.5

18.5±4.8

<0.0001

LDL ARV

18.4±9.6

17.7±9.5

19.0±9.6*

13.7±5.8

23.0±10.3

<0.0001

  1. Values were means (SD) or median (quartile). VIM indicates variability independent of the mean; ARV, average real variability; and MMD, the difference of maximum minus minimum LDL. aThe Fenofibrate vs. Placebo group, *P<0.001; †P<0.01; and ‡P<0.05. bHigh vs. Low VIM, and the P value is given